July 2017

Anju Software, a life sciences software platform backed by Providence Equity Partners, has acquired the ClinPlus, a division of DZS Software Solutions.

  • With this acquisition Anju provides full clinical trial software support from Phase 1 to Phase 4 with a scalable web platform for CROs and pharma companies
  • ClinPlus offers a full suite of products used for the performance of clinical trials including EDC, IWRS, CTMS, eTMF, Data Management, Coding and SAS Reporting

About Anju Software

Anju Software is a life sciences enterprise software platform focused on delivering exceptional business application solutions with outstanding customer support. Anju was founded by a group of operating and investment professionals with deep software domain expertise and a proven track record of building software platforms through strategic acquisitions and organic growth.

About DZS Software Solutions

DZS Software Solutions, Inc. is a privately held company founded in 1996 and providing clinical trials software to the biotech and pharmaceutical industry worldwide. DZS will retain DZS Clinical Services, a division of DZS Software Solutions, which is a full service CRO having supported numerous drug approvals, conducted hundreds of clinical studies for both large and small pharmaceutical and biotech companies for a variety of clinical indications. DZS Clinical services use the ClinPlus product suite which is now part of Anju.

About Providence Equity

Providence is a premier asset management firm with over $40 billion in aggregate capital commitments. Providence pioneered a sector-focused approach to private equity investing with the vision that a dedicated team of industry experts could build exceptional companies of enduring value. Since the firm’s inception in 1989, Providence has invested in over 180 companies and has become a leading equity investment firm focused on the media, communications, education and information industries.

Acquisition of

Client Highlights

Transaction Details

“We are pleased with the execution of the growth strategy of Anju with ClinPlus being the third acquisition in a year. After having established a dominant position in Medical Affairs with the acquisition of OBA and OpenIQ, ClinPlus will enable Anju to enter and grow in the clinical trial space.”
Gopi Vaddi, Managing Director, Providence Strategic Growth

Get in touch with us

Contact Us

  • Hidden
  • This field is for validation purposes and should be left unchanged.